Update on selection of optimal radiopharmaceuticals for clinical trials

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 6, 2008, Pages 797-806

  Williams, Lawrence E ^a   Lopatin, George ^b   Kaplan, Daniel D ^c   Liu, An ^d   Wong, Jeffrey Y C ^d  

^a Division of Radiology   (United States)

^b Stanford University School of Medicine ^*  (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Division of Radiation Oncology   (United States)

Author keywords

Allometry; Antibodies; Figures of merit; IFOM; Radiopharmaceutical selection; TFOM

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; INDIUM 111; IODINE 131; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ALLOMETRY; ANTIBODY LABELING; AREA UNDER THE CURVE; COMPUTER ASSISTED TOMOGRAPHY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG FORMULATION; FECES; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; KINETICS; MATHEMATICAL MODEL; MEDICAL RESEARCH; MOLECULAR WEIGHT; MONTE CARLO METHOD; NANOENGINEERING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ENGINEERING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; URINARY EXCRETION; ANIMAL; CLINICAL TRIAL; MOUSE; NEOPLASM;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; MICE; NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 58549085779     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0534     Document Type: Review

References (23)

1. Frilling A, Weber F, Cincinnati V, et al. Role of radiolabeled octreotide therapy in patients with metastatic neuroendocrine neoplasms. Exp Rev Endocrinol Metab 2007;2:517.
2. Iznaga-Escobar N, Mishra AK, Perez-Rodriquez R. Factors affecting pharmacokinetics of monoclonal antibodies: A review article. Meth Find Exp Clin Pharmacol 2004;26:123.
3. Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002;4:95.
4. DeNardo GL, Natarajan A, Hok S, et al. Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma. J Nucl Med 2007;48:1338.
5. Yang G, Cai K, Thompson-Lanza JA, et al. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem 2004;279:4339.
6. Hicke BJ, Stephens AW, Gould T, et al. Tumor targeting by an aptamer. J Nucl Med 2006;47:668.
7. Kukowska-Latallo JF, Candido KA, Cao Z, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Research 2005;65:5317.
8. Gagne RM, Boswell JS, Meyers KJ. Signal detectability in digital radiography: Spatial domain figures of merit. Med Phys 2003;30:2180.
9. West GB, Brown JH. Life's universal scaling laws. Phys Today 2004;57:36.
10. Yazaki PJ, Wu AM, Tsai S-W, et al. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and T84.66 minibody: Comparison to radioiodinated fragments. Bioconjugate Chem 2001;12:220.
11. 2 fragment in nude mice bearing different human colon cancer xenografts. Cancer 1993;68:684.
12. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer 2007;7:645.
13. Tukey JW. Exploratory Data Analysis. New York: Addison-Wesley, 1977.
14. Jacquez JA. Compartmental Analysis in Biology and Medicine, 2nd ed. Ann Arbor, MI: University of Michigan Press, 1985.
15. Ruppert D, Wand MP, Carroll RJ. Semiparametric Regression. Cambridge: Cambridge University Press, 2003.
16. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm 1990;3:213.
17. Sgouros G, Stabin M, Erdi Y, et al. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. Med Phys 2000;21;2150.
18. Odom-Maryon TL, Williams LE, Chai A, et al. Pharmacokinetic modeling and absorbed dose estimation for chimerical anti-CEA antibody in humans. J Nucl Med 1997;38:1959.
19. Stern P, Hagan P, Halpern S, et al. The effect of radiolabel on the kinetics of monoclonal anti-CEA in a nude mouse-human colon tumor model. In: Mitchell M, Oettgen H, eds. Hybridomas in Cancer Diagnosis and Treatment, Vol. 21. New York: Raven, 1982:245.
20. Williams LE, Wu AM, Yazaki PJ, et al. Numerical selection of optimal tumor-imaging agents with application to engineered antibodies. Cancer Biother Radiopharm 2001;16:25.
21. Williams LE, Duda RB, Proffitt RT, et al. Tumor uptake as a function of tumor mass: A mathematic model. J Nucl Med 1988;29:103.
22. Williams LE, Liu A, Wu AM, et al. Figures of merit (FOMs) for imaging and therapy using monoclonal antibodies. Med Phys 1995;22:2025.
23. Khor SP, McCarthy K, DuPont M, et al. Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL-Ig for phase 1 trial. J Pharm Exp Ther 2000;293:618.